## Management of Advanced Laryngeal Carcinoma (T4a N1-3 M0) ### Clinical Staging Assessment **Key Point:** This patient has: - **T4a disease:** Tumor invading thyroid cartilage (invasion beyond laryngeal framework) - **N1 disease:** Single ipsilateral lymph node 2 cm (meets N1 criteria) - **M0:** No distant metastases - **Overall Stage IVA** (T4a N1 M0) ### Treatment Algorithm for Stage IVA Laryngeal Carcinoma ```mermaid flowchart TD A[Stage IVA Laryngeal Cancer<br/>T4a N1-3 M0]:::outcome --> B{Laryngeal Function<br/>Preservation Goal?}:::decision B -->|Yes| C[Concurrent Chemoradiation<br/>CCRT 70 Gy + Cisplatin]:::action B -->|No| D[Total Laryngectomy<br/>+ Bilateral Neck Dissection]:::action C --> E{Response at 8-12 weeks?}:::decision E -->|Complete Response| F[Observation]:::action E -->|Residual Neck Disease| G[Planned Neck Dissection]:::action E -->|Local Failure| H[Salvage Laryngectomy]:::urgent D --> I[Adjuvant RT ± CT<br/>if high-risk features]:::action ``` ### Evidence-Based Treatment Comparison | Modality | Indication | Outcome | Voice Quality | |----------|-----------|---------|---------------| | **CCRT** | T4a N0-3 M0; good performance status; no severe comorbidities | 5-yr OS ~50–60%; laryngeal preservation in 60–70% | Preserved (if successful) | | **Total Laryngectomy** | T4a with cartilage invasion; failed CCRT; poor performance status; airway compromise | 5-yr OS ~50–60%; definitive local control | Lost (requires alaryngeal speech) | | **RT alone** | Medically unfit for chemotherapy; palliative intent | Inferior outcomes vs CCRT; ~40% 5-yr OS | Variable | | **TLM** | Early T1-T2 glottic tumors; NOT suitable for T4a with cartilage invasion | Not applicable for advanced disease | Preserved | **High-Yield:** The landmark **VA Laryngeal Cancer Study (1991)** and **RTOG 91-11 trial (2003)** demonstrated that concurrent chemoradiation (cisplatin 100 mg/m² on days 1, 22, 43 of RT) achieves superior laryngeal preservation rates (~88%) compared to RT alone (~68%) in patients with T3-T4a N0-3 M0 disease, with acceptable toxicity in fit patients. **Clinical Pearl:** - **Laryngeal preservation strategy** is the preferred first-line approach in fit patients (ECOG 0–1, adequate renal/hearing function) with T4a disease because it maintains voice and swallowing. - **Planned neck dissection** is performed 8–12 weeks post-CCRT if residual lymphadenopathy >1 cm persists on imaging (CT or PET-CT). - **Salvage laryngectomy** is offered to patients with local recurrence after CCRT, with 5-year survival ~30–40%. **Mnemonic - CCRT Indications in Head & Neck Cancer: **STAGE** - **S**quamous cell carcinoma - **T**3-T4 or N2-N3 disease - **A**dvanced (Stage III–IVA) - **G**ood performance status (ECOG 0–1) - **E**ligible (adequate renal/cardiac function, no severe hearing loss) 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.